Antihypertensive efficacy of metoprolol XL/low dose chlorthalidone (6.25 mg) combination: A randomized, comparative study in Indian patients with mild-to-moderate essential hypertension

European Journal of Medical Research

Volumn 14, Issue 7, 2009, Pages 297-303

  Pareek, Anil ^a   Zawar, S D ^b   Salagre, S B ^c   Chandurkar, N B ^d   Karnik, N D ^e  

^a Ipca Laboratories Ltd   (India)

^b GOVERNMENT MEDICAL COLLEGE   (India)

^c KEM HOSPITAL   (India)

^d Ipca Laboratories Limited   (India)

^e LOKMANYA TILAK MUNICIPAL GENERAL HOSPITAL   (India)

Author keywords

Beta blocker; Chlorthalidone; Diuretics; Essential hypertension; Metoprolol

Indexed keywords

CHLORIDE ION; CHLORTALIDONE; GLUCOSE; HYDROCHLOROTHIAZIDE; METOPROLOL; POTASSIUM ION; SODIUM ION; ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; ELECTROLYTE BLOOD LEVEL; ESSENTIAL HYPERTENSION; GLUCOSE BLOOD LEVEL; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; ADULT; BLOOD PRESSURE; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECT; FEMALE; HYPERTENSION; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; TIME; TREATMENT OUTCOME;

ADULT; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CHLORTHALIDONE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; METOPROLOL; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME;

EID: 70149095350     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: 10.1186/2047-783x-14-7-297     Document Type: Article

References (26)

1. Kjeldsen SE, Julius S, Hedner T, Hanson L. Stroke is more common than myocardial infarction in hypertension: analysis based on 11 major randomized intervention trials Blood Press 2001;10:190-192
2. Scholze J, Bida M, Hansen A et al. Initiation of hypertension treatment with a fixed-dose combination or its monocomponents - Does it really matter? Int J Clinical Pract.2006;60:265-274.
3. Mancia G. Blood pressure reduction and cardiovascular outcomes: past, present and future. Am J Cardiol 2007, 100:3J-9J Epub 2007 May 25.
4. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
5. Wright JT, Dunn JK, Cutler JA et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA. 2005; 293:1595-1608.
6. Psaty BM, Lumley T, Furberg CD et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003 21;289:2534-2544. (Pubitemid 37430155)
7. Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group. JAMA. 1979;242:2562-2571.
8. The Multiple Risk Factor Intervention Trial Research Group (MRFIT). Mortality rates after 10.5 years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation. 1990;82:1616-1628.
9. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255-3264.
10. Neaton JD, Grimm RH, Prineas RJ et al. Treatment of mild hypertension study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA. 1993;270:713-724.
11. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003; 289:2560-2572. (Pubitemid 37430158)
12. Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension 2004;43:4-9. Epub 2003 Nov 24.
13. Ernst ME, Carter BL, Goerdt CJ et al. Comparative antihypertensive effects of hydrochlorothiazide and chlor thalidone on ambulatory and office blood pressure. Hypertension 2006;47:352-358. Epub 2006 Jan 23.
14. Cushman WC, Ford CE, Cutler JA et al. Success and predictors of blood pressure control in diverse North American Settings: The Antihypertensive and Lipid - Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens. 2002;4:393-404.
15. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood -pressure lowering and low dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT Study Group. Lancet 1998;13;351:1755-1762 (Pubitemid 28269185)
16. Black HR, Elliot WJ, Grandits G, et al. Principal results of the Controlled Onset Verapramil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003;289:2073-2082 (Pubitemid 37430209)
17. Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in Hypertensive Study. (LIFE): A randomized trial against atenolol. Lancet 2002;359:995-1003.
18. Materson BJ, Reda DJ, Cushman WC et al. Single - drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993;328:914-921
19. European Society of Hypertension. European Society of Cardiology Guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-1053 (Pubitemid 36667855)
20. Zidek W. Hochdruckleitlinien iiberabeitet. Was ist Praxis-relevant? MMW Fortschr Med 2004;1-2:16/37-8/17.
21. Dabovisek J, Kanic V, Niegowska J, Rekic S, Soucek M, Spinar J. Efficacy and tolerability of losartan in patients with essential hypertension: a multicentre, double blind comparison of losartan with metoprolol. J Clin Basic Cardiol 2005;8:43-46 (Pubitemid 43175079)
22. Bichisao E, Merlini L, Gambini O, Alberti D, Pollavini G. Chlorthalidone alone or in fixed combination with slow-release metoprolol in the management of arterial hypertension: a long-term study of 545 patients. J Int Med Res. 1989;17:339-349 (Pubitemid 19193538)
23. Jaattela A, Pyorala K. A controlled study on the antihypertensive effect of a new beta-adrenergic receptor blocking drug, metoprolol, in combination with chlorthalidone. Br J Clin Pharmacol 1976;3:655-660
24. Kieso HA, Gould BA, Mann S, Hornung RS, Altman DG, Raftrey EB. Effect on intra-arterial blood pressure of slow release metoprolol combined with placebo or chlorthalidone. Br Med J (Clin Res Ed.) 1983;287:717-720.
25. Pareek A, Karnik N, Salagre S, Zawar S, Joglekar V, Chandurkar N et al. Clinical effectiveness of low-dose chlorthalidone (6.25 mg) + atenolol combination in stage I hypertensive patients: a multicentre, randomized, controlled study. Curr Med Res Opin 2008,24:1771-1779 (Pubitemid 351929074)
26. Pareek A, Basavanagowdappa H, Zawar S, Kumar A, Chandurkar N. A randomized, comparative study evaluating the efficacy and safety of combination of losartan with low dose chlorthalidone (6.25 mg) versus losartan with hydrochlorothiazide combination in Indian patients with mild to moderate essential hypertension. Jackson Cardiovascular-Renal Meeting 2008. The university of Mississippi Medical Center